Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6

University of California, Los Angeles (UCLA)

Status and phase: Completed; Phase 2

Conditions: Cocaine-Related Disorders

Treatments: Drug: Baclofen

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000303

P50DA009260 (U.S. NIH Grant/Contract)

P50-09260-6

NIDA-09260-6

Details and patient eligibility

About

The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. In this study, baclofen is tested.

Full description

16-week participation plus a 2 week lead in period. Participants are assigned randomly to placebo or baclofen. Participant attend group meetings 3 x/week.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

M/F ages 18-65. cocaine dependence according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.

Exclusion criteria

Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or nursing women, dependence on ethanol (ETOH) or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.